ITEM VIEW

An overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3)

dc.contributor.authorVan Rensburg, R.en_ZA
dc.contributor.authorReuter, H.en_ZA
dc.date.accessioned2021-09-01T10:45:48Z
dc.date.available2021-09-01T10:45:48Z
dc.date.issued2019
dc.identifier.citationVan Rensburg, R. & Reuter, H. 2019. An overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3). South African Family Practice, 61(3):a4972, doi:10.4102/safp.v61i3.4972
dc.identifier.issn2078-6204 (online)
dc.identifier.issn2078-6190 (print)
dc.identifier.otherdoi:10.4102/safp.v61i3.4972
dc.identifier.otherdoi:10.4102/safp.v61i3.4972
dc.identifier.urihttp://hdl.handle.net/10019.1/122980
dc.descriptionCITATION: Van Rensburg, R. & Reuter, H. 2019. An overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3). South African Family Practice, 61(3):a4972, doi:10.4102/safp.v61i3.4972.
dc.descriptionThe original publication is available at https://safpj.co.za
dc.description.abstractENGLISH ABSTRACT: Pain is classified by various descriptions. Chronic pain has been described as being neuropathic (due to nervous system lesions), nociceptive (due to tissue damage), or mixed (a combination of neuropathic and nociceptive). The addition of the term nociplastic pain is used to describe patients who experience chronic pain without tissue damage or nervous system lesions. Chronic pain is often difficult to manage, particularly neuropathic pain. Evidence-based pharmacological treatment options include anticonvulsants and antidepressants. The choice of medication will depend on various factors, including patient profile, type of pain, and associated conditions. Medications with the best evidence of efficacy for first-line use in neuropathic pain are the gabapentinoids, carbamazepine, the tricyclic antidepressants, and the serotonin-noradrenaline reuptake inhibitors duloxetine and venlafaxine. The cannabinoids and ketamine are being actively investigated for use in chronic pain. Currently the cannabinoids’ potential benefit is outweighed by the adverse effects, and recommendations for the use of ketamine is limited by its parenteral route of administration and low evidence of efficacy in chronic pain.en_ZA
dc.description.urihttps://safpj.co.za/index.php/safpj/article/view/4972
dc.format.extent5 pagesen_ZA
dc.language.isoen_ZAen_ZA
dc.publisherAOSISen_ZA
dc.subjectNeuropathic painen_ZA
dc.subjectAnticonvulsantsen_ZA
dc.subjectAntidepressantsen_ZA
dc.subjectCannabinoidsen_ZA
dc.titleAn overview of analgesics - anticonvulsants, antidepressants, and other medications (Part 3)en_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher's version
dc.rights.holderAuthors retain copyrighten_ZA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW